Dermatologicals Market Size, Share, Growth, Trends, Production, Consumption, Revenue and Forecast 2020 to 2027

Table of Content

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments

1.2.1. List of key players profiled in the report

1.3. Research methodology

1.3.1. Primary research
1.3.2. Secondary research
1.3.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Top player positioning

3.2.1. Top investment pockets

3.3. Key forces shaping dermatologicals industry/market
3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Increase in prevalence of skin disorders
3.4.1.2. Surge in healthcare expenditure worldwide
3.4.1.3. Rise in focus on skin care products

3.4.2. Restraint

3.4.2.1. Presence of alternatives for acne treatment

3.4.3. Opportunity

3.4.3.1. High growth potential in developing economies

3.4.4. Impact Analyses

CHAPTER 4: DERMATOLOGICALS MARKET, BY DISEASE

4.1. Overview

4.1.1. Market size and forecast

4.2. Acne

4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country

4.3. Dermatitis

4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country

4.4. Psoriasis

4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country

4.5. Skin Cancer

4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country

4.6. Rosacea

4.6.1. Key market trends, growth factors, and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country

4.7. Alopecia

4.7.1. Key market trends, growth factors, and opportunities
4.7.2. Market size and forecast, by region
4.7.3. Market analysis, by country

4.8. Others

4.8.1. Key market trends, growth factors, and opportunities
4.8.2. Market size and forecast, by region
4.8.3. Market analysis, by country

CHAPTER 5: DERMATOLOGICALS MARKET, BY TYPE

5.1. Overview

5.1.1. Market size and forecast

5.2. Prescription-Based Drugs

5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country

5.3. Over-the-Counter Drugs

5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country

CHAPTER 6: DERMATOLOGICALS MARKET, BY ROUTE OF ADMINSTRATION

6.1. Overview

6.1.1. Market size and forecast

6.2. Topical Administration

6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country

6.3. Oral Administration

6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country

6.4. Parenteral Administration

6.4.1. Market size and forecast, by region
6.4.2. Market analysis, by country

CHAPTER 7: DERMATOLOGICALS MARKET, BY REGION

7.1. Overview

7.1.1. Market size and forecast

7.2. North America

7.2.1. Key market trends and opportunities
7.2.2. Market analysis, by country

7.2.2.1. U.S.

7.2.2.1.1. U.S. market size and forecast, by disease
7.2.2.1.2. U.S. market size and forecast, by type
7.2.2.1.3. U.S. market size and forecast, by route of administration

7.2.2.2. Canada

7.2.2.2.1. Canada market size and forecast, by disease
7.2.2.2.2. Canada market size and forecast, by type
7.2.2.2.3. Canada market size and forecast, by route of administration

7.2.2.3. Mexico

7.2.2.3.1. Mexico market size and forecast, by disease
7.2.2.3.2. Mexico market size and forecast, by type
7.2.2.3.3. Mexico market size and forecast, by route of administration

7.2.3. North America market size and forecast, by disease
7.2.4. North America market size and forecast, by type
7.2.5. North America market size and forecast, by route of administration

7.3. Europe

7.3.1. Key market trends and opportunities
7.3.2. Market analysis, by country

7.3.2.1. Germany

7.3.2.1.1. Germany market size and forecast, by disease
7.3.2.1.2. Germany market size and forecast, by type
7.3.2.1.3. Germany market size and forecast, by route of administration

7.3.2.2. France

7.3.2.2.1. France market size and forecast, by disease
7.3.2.2.2. France market size and forecast, by type
7.3.2.2.3. France market size and forecast, by route of administration

7.3.2.3. UK

7.3.2.3.1. UK market size and forecast, by dermatological disease
7.3.2.3.2. UK market size and forecast, by type
7.3.2.3.3. UK market size and forecast, by route of administration

7.3.2.4. Italy

7.3.2.4.1. Italy market size and forecast, by dermatological disease
7.3.2.4.2. Italy market size and forecast, by type
7.3.2.4.3. Italy market size and forecast, by route of administration

7.3.2.5. Rest of Europe

7.3.2.5.1. Rest of Europe market size and forecast, by dermatological disease
7.3.2.5.2. Rest of Europe market size and forecast, by type
7.3.2.5.3. Rest of Europe market size and forecast, by route of administration

7.3.3. Europe market size and forecast, by dermatological disease
7.3.4. Europe market size and forecast, by type
7.3.5. Europe market size and forecast, by route of administration

7.4. Asia-Pacific

7.4.1. Key market trends and opportunities
7.4.2. Market analysis, by country

7.4.2.1. Japan

7.4.2.1.1. Japan market size and forecast, by dermatological disease
7.4.2.1.2. Japan market size and forecast, by type
7.4.2.1.3. Japan market size and forecast, by route of administration

7.4.2.2. China

7.4.2.2.1. China market size and forecast, by dermatological disease
7.4.2.2.2. China market size and forecast, by type
7.4.2.2.3. China market size and forecast, by route of administration

7.4.2.3. India

7.4.2.3.1. India market size and forecast, by dermatological disease
7.4.2.3.2. India market size and forecast, by type
7.4.2.3.3. India market size and forecast, by route of administration

7.4.2.4. Rest of Asia-Pacific

7.4.2.4.1. Rest of Asia-Pacific market size and forecast, by dermatological disease
7.4.2.4.2. Rest of Asia-Pacific market size and forecast, by type
7.4.2.4.3. Rest of Asia-Pacific market size and forecast, by route of administration

7.4.3. Asia-Pacific market size and forecast, by dermatological disease
7.4.4. Asia-Pacific market size and forecast, by type
7.4.5. Asia-Pacific market size and forecast, by route of administration

7.5. LAMEA

7.5.1. Key market trends and opportunities
7.5.2. Market analysis, by country

7.5.2.1. Brazil

7.5.2.1.1. Brazil market size and forecast, by dermatological disease
7.5.2.1.2. Brazil market size and forecast, by type
7.5.2.1.3. Brazil market size and forecast, by route of administration

7.5.2.2. South Africa

7.5.2.2.1. South Africa market size and forecast, by dermatological disease
7.5.2.2.2. South Africa market size and forecast, by type
7.5.2.2.3. South Africa market size and forecast, by route of administration

7.5.2.3. Saudi Arabia

7.5.2.3.1. Saudi Arabia market size and forecast, by dermatological disease
7.5.2.3.2. Saudi Arabia market size and forecast, by type
7.5.2.3.3. Saudi Arabia market size and forecast, by route of administration

7.5.2.4. Rest of LAMEA

7.5.2.4.1. Rest of LAMEA market size and forecast, by dermatological disease
7.5.2.4.2. Rest of LAMEA market size and forecast, by type
7.5.2.4.3. Rest of LAMEA market size and forecast, by route of administration

7.5.3. LAMEA market size and forecast, by dermatological disease
7.5.4. LAMEA market size and forecast, by type
7.5.5. LAMEA market size and forecast, by route of administration

CHAPTER 8: COMPANY PROFILES

8.1. AbbVie Inc.

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance

8.2. AstraZeneca plc

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments

8.3. Amgen Inc.

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance

8.4. GlaxoSmithKline Plc.

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance

8.5. Johnson & Johnson

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance

8.6. Leo Pharma A/S

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments

8.7. Merck KGaA

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance

8.8. Nestlé S.A

8.8.1. Company overview
8.8.2. Operating business segments
8.8.3. Business performance

8.9. Novartis AG

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance

8.10. Pfizer Inc.

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance

Report Details

  • Report Code:34662
  • Category:Healthcare
  • No. of Pages:200
  • Format:PDF/PPT/Excel
  • Published:January 2020
  • Historical Year:2021-2022
  • Base Year:2023
  • Estimated Year:2024-2033

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers